

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-15 (canceled)

R 16. (Currently Amended) A pharmaceutical formulation for peroral single daily application, comprising clarithromycin or a derivative thereof and a mixture of a fatty and hydrophilic component, wherein the fatty component comprises about 10-36 weight percent of the formulation, and wherein the hydrophilic component comprises about 5-18 weight percent of the formulation

17. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, further comprising a surfactant.

18. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, further comprising a pH modulator.

19. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, wherein the fatty component comprises glyceryl behenate.

20. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, wherein the hydrophilic component comprises hydroxypropyl methylcellulose of low viscosity.

21. (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 19, wherein the hydroxypropyl methylcellulose has a viscosity of about 15 cP.

~~22.~~ (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 17, wherein the surfactant comprises sodium docusate.

~~23.~~ (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 18, wherein the pH modulator comprises a phosphate buffer.

~~24.~~ (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim 16, characterized in that it is in the form of a tablet.

~~25.~~ (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim ~~23~~ 24, characterized in that the tablet is lacquered.

~~26.~~ (Currently Amended) ~~A~~ The pharmaceutical formulation according to claim ~~23~~ 24, characterized in that on the tablet an acid-resistant coating is applied.

~~27.~~ (Currently Amended) A process for the preparation of a pharmaceutical formulation for peroral single daily application comprising clarithromycin or a derivative thereof and a mixture of a fatty and a hydrophilic component, wherein the fatty component comprises about 10-36 weight percent of the formulation, and wherein the hydrophilic component comprises about 5-18 weight percent of the formulation, which comprises forming a homogeneous mixture thereof and direct compressing said mixture into tablet form without use of solvents.

~~28.~~ (Currently Amended) ~~A~~ The process according to claim 27 comprising sieving the homogeneous mixture prior to compressing the mixture into tablet form.

~~29.~~ (New) The pharmaceutical formulation according to claim 24, wherein the fatty component is a sustained released component that provides sustained release of the clarithromycin or clarithromycin derivative, and wherein the hydrophilic component forms a viscous layer in an aqueous medium through which the clarithromycin or clarithromycin

derivative diffuses upon solubilization, and wherein the fatty component and the hydrophilic component are in a weight ration to each other between about 2:1 to 10:1, thereby effective to provide controlled release of the clarithromycin or clarithromycin derivative over about a twenty-four hour period.

~~30.~~ (New) The pharmaceutical formulation according to claim 29, wherein the fatty component is selected from a group of fatty components consisting of triglycerides of higher saturated fatty acids, hydrogenated oils and mixtures thereof.

B'
com.
~~31.~~ (New) The pharmaceutical formulation according to claim 29, wherein the fatty component is glyceryl behenate.

~~32.~~ (New) The pharmaceutical formulation according to claim 29, wherein the hydrophilic component is selected from a group of hydrophilic components consisting of alkyl-substituted cellulose ethers, fatty alcohols, polysaccharides, large specific surface absorbents and mixtures thereof.

~~33.~~ (New) The pharmaceutical formulation according to claim 32, wherein the hydrophilic component is selected from a group of hydrophilic components consisting of alkyl-substituted cellulose ethers and mixtures thereof.

~~34.~~ (New) The pharmaceutical formulation according to claim 33, wherein the fatty component is glyceryl behenate, and wherein the hydrophilic component is hydroxypropyl methylcellulose.
